A randomised double blind phase 2 trial of whole brain radiotherapy with or without vandetanib in metastatic melanoma with brain metastases

Trial Profile

A randomised double blind phase 2 trial of whole brain radiotherapy with or without vandetanib in metastatic melanoma with brain metastases

Discontinued
Phase of Trial: Phase II

Latest Information Update: 06 Oct 2016

At a glance

  • Drugs Vandetanib (Primary)
  • Indications Brain metastases; Malignant melanoma
  • Focus Therapeutic Use
  • Acronyms RADVAN
  • Most Recent Events

    • 06 Oct 2016 Primary endpoint (Efficacy of vandetanib in combination with radiotherapy, compared with radiotherapy; Timepoint(s): Progression free survival in brain (as assessed by MRI scan))has not been met, according to results published in the British Journal of Cancer.
    • 06 Oct 2016 Results published in the British Journal of Cancer
    • 12 Sep 2014 Accrual to date is 27% according to United Kingdom Clinical Research Network
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top